| Attributes | Values |
|---|
| rdf:type
| |
| description
| - wetenschappelijk artikel (nl)
- наукова стаття, опублікована у квітні 2011 (uk)
- article scientifique publié en 2011 (fr)
- artículu científicu espublizáu n'abril de 2011 (ast)
- scientific article published on 04 April 2011 (en)
|
| publication date
| |
| publication date
| |
| author name string
| |
| author name string
| - Eric Van Cutsem
- Claus-Henning Köhne
- Malcolm Moore
- J Randolph Hecht
- Emilio Bajetta
- Edward Lin
- David Lebwohl
- Dirk Laurent
- Bee-Lian Chen
- Gerold Meinhardt
- William Berg
- Tarja Jalava
- Colin Germond
|
| rdfs:label
| - Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma (en)
- Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma (nl)
|
| skos:prefLabel
| - Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma (en)
- Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma (nl)
|
| name
| - Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma (en)
- Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma (nl)
|
| author
| |
| author
| |
| title
| |
| title
| - Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma (en)
|
| page(s)
| |
| page(s)
| |
| instance of
| |
| instance of
| |
| main subject
| |
| main subject
| |
| PubMed ID
| |
| PubMed ID
| |
| PubMed ID
| |
| published in
| |
| published in
| |
| issue
| |
| volume
| |
| issue
| |
| volume
| |
| DOI
| |
| DOI
| |
| DOI
| |
| is about
of | |
| is cites work
of | - The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management
- VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside
- Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials
- Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
- Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups
- Isolated hepatic perfusion for patients with liver metastases
- The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management
- Initial LDH level can predict the survival benefit from bevacizumab in the first-line setting in Chinese patients with metastatic colorectal cancer
- Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients
- Antiangiogenesis therapy in the treatment of metastatic colorectal cancer
- Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study
- Angiogenic inhibitors for older patients with advanced colorectal cancer: does the age hold the stage?
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
- Anti-angiogenic therapies for metastatic colorectal cancer: current and future perspectives
- The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials
- Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer: standard of care or an experimental approach?
- Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205.
- Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer
- Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).
- Hepatic arterial infusion pump chemotherapy in the management of colorectal liver metastases: expert consensus statement
- Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study.
- Longterm effects of palliative local treatment of incurable metastatic lesions in colorectal cancer patients
- A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma
- Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New
- The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib.
- Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials
- Intermittent dosing of axitinib combined with chemotherapy is supported by (18)FLT-PET in gastrointestinal tumours
- Anti-angiogenic agents in metastatic colorectal cancer
- Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment
- Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management
|
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)